Fascinating Proteinuria Therapeutics Market Tactics That Can Help Your Business Grow

The global proteinuria therapeutics market is expected to grow at a CAGR of 2.50% during the forecast period. The major challenges affecting the growth of the proteinuria therapeutics market include lack of curative therapies, adverse effects of available therapeutics, and stringent regulations.

Get Free Sample

The treatment of proteinuria mainly requires a proper diagnosis of the underlying cause. In patients with proteinuria due to hypertension, the therapeutics for treatment mostly consists of ACE inhibitors, which are also first-line therapy for proteinuria. Moreover, in patients whose proteinuria is not controlled with the use of ACE inhibitors, an aldosterone antagonist or ARBs are added to reduce the protein content in the urine. 

Currently, the global proteinuria therapeutics market does not have any approved and curative therapies. The market is dominated by various off-label drugs for the treatment of the underlying condition. The secondary nature and multifactorial etiology of the condition make a clinical trial evaluation of drug candidates difficult. Drugs tested in such trials also fail to provide statistically significant results, even if they demonstrate high efficacy and are safe for administration. Thus, the lack of curative drug therapies is expected to hinder the growth of the proteinuria therapeutics market. However, despite the challenges the market is expected to witness an accelerating momentum during the forecast period. 

Sponsor Ads

• Ad Space Available - Rent it Now!

Report this Page

Created on Oct 31st 2019 05:44. Viewed 359 times.

Share on APSense

Comments